Compare Crispr Therapeutics AG (CRSP) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Marriott International Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Marriott International Inc trades at $365.88 (market cap $94.16B). The key difference: Marriott International Inc is far larger — about 19.3× Crispr Therapeutics AG's market cap, and Marriott International Inc pays a 0.81% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Marriott International Inc for 164 Days on average.
| CRSP | MAR | |
|---|---|---|
Market Cap | $4.88B | $94.16B |
Volume | 2,861,747 | 996,176 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $402.54 |
52-Week Low | $44.34 | $259.04 |
Typical Hold Time | 77 Days | 164 Days |
Enterprise Value | $3.30B | $111.47B |
Dividend Yield | — | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Marriott International (MAR) trades at $365.88, up 2.63% with strong technical momentum and bullish moving averages. The company shows solid revenue growth to $26.19B in 2025 and consistent earnings beats, though valuation ratios remain elevated with a P/E of 37.38. Recent developments include strategic technology partnerships and dividend declarations, while institutional activity shows mixed positioning adjustments.
Outlook remains positive with analyst consensus target of $386.71 offering 5.7% upside potential. Key opportunities include travel recovery momentum and operational efficiency gains, while risks center on high debt levels (debt-to-asset ratio of 58.83%) and potential economic sensitivity. The stock presents a balanced risk-reward profile with moderate growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
